Baclofen - a great chance or danger - discussion of poisoning based on research
DOI:
https://doi.org/10.12775/JEHS.2023.45.01.006Keywords
baclofen, spasticity, intoxication, toxicity, muscle tensionAbstract
Introduction and purpose: Baclofen is a derivative of γ-aminobutyric acid (GABA). It is a spasmolytic drug that reduces skeletal muscle tension and is used in spasticity. Despite its many positive functions, its use is associated with a risk of side effects. The aim of this work is to gain a better understanding of baclofen and to highlight the toxicity and dangers of its misuse.
Material and methods: The study was retrospective in nature. It used an analysis of the records of 11648 intoxications in patients hospitalised from 01.04.2013 to 01.04.2023 in the Clinical Toxicology and Cardiology Department of the Stefan Cardinal Wyszyński Provincial Hospital in Lublin, from which a group of baclofen intoxicated patients (T55), consisting of 19 cases, was distinguished.
Results: The study population consisted of 10 women (52.63%) and 9 men (47.37%), aged between 16 and 83 years. The largest group consisted of patients aged up to 30 years - 9 patients (47.37%). The majority of patients - 11 patients (59.89%) were in a severe condition. An overwhelming number reported intentional poisoning - 16 cases (84.21%), including five suicide attempts (31.25%). Patients took other drugs and medicines in addition to baclofen. The most common was ethanol - 8 people (42.11%), followed by NSAIDs - 5 people (26.32%).
Conclusions: In order to prevent complications following the use of baclofen, it is very important to educate patients, their family members and the general public about the mechanism of action of the drug itself, its function on the body and the risks of taking it. Prophylactic measures and education on how to deal with poisoning situations are necessary, as they are entirely preventable with immediate diagnosis and treatment.
References
C. N. Kent, Ch Park, C. W Lindsley; Classics in Chemical Neuroscience: Baclofen; ACS Chem Neurosci. 2020 Jun 17;11(12):1740-1755.; PMID: 32436697 DOI: 10.1021/acschemneuro.0c00254
W. Lake, H. Shah; Intrathecal Baclofen Infusion for the Treatment of Movement Disorders; Neurosurgery Clinics of North America Volume 30, Issue 2, April 2019, Pages 203-209 https://doi.org/10.1016/j.nec.2018.12.002;
M. Ghannoum, I. Berling, V. Lavergne, D.M. Roberts, T. Galvao, R.S. Hoffman, T. D. Nolin, A. Lewington, K. Doi, S. Gosselin; Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning; Kidney International Volume 100, Issue 4, October 2021, Pages 720-736; https://doi.org/10.1016/j.kint.2021.07.014
P.S. Jagpal; Ekspozycja na baklofen zgłaszana do brytyjskiego National Poisons Information Service (NPIS) w ciągu 12 lat (2005-2017); [Baclofen exposures reported to the UK National Poisons Information Service (NPIS) over 12 years (2005-2017)];Clin Toxicol(2018)
Baklofen (opis profesjonalny); [ Baclofen (professional description)]; Baza leków Substancje od A do Z Baklofen; [ Drug Database Substances A to Z Baclofen] https://www.mp.pl/pacjent/leki/subst.html?id=115
R. de Beaurepaire, J. M. A. Sinclair, M. Heydtmann, G. Addolorato, H.J Aubin, E.M. Beraha, F. Caputo, J. D. Chick, P. de La Selle, N. Franchitto, J. C. Garbutt, P.S. Haber, P. Jaury, A. R. Lingford-Hughes, K. C. Morley, C. A. Müller, L. Owens, A. Pastor, L. M. Paterson, F. Pélissier, B. Rolland, A. Stafford, A. Thompson, W.van den Brink, L. Leggio, R. Agabio; The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective; REVIEW article; Front. Psychiatry, 04 January 2019; Sec. Addictive Disorders; Volume 9 – 2018; https://doi.org/10.3389/fpsyt.2018.00708
R. Agabio, G. Colombo; Ligandy receptora GABAB do leczenia zaburzeń związanych z używaniem alkoholu: dowody przedkliniczne i kliniczne; [GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.]; Front Neurosci . (2014) 8:140. doi: 10.3389/fnins.2014.00140
Dario A, Tomei G. Ocena stosunku korzyści do ryzyka baklofenu w ciężkiej spastyczności kręgosłupa. [A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity]; Bezpieczny lek . (2004) 27:799-818. doi: 10.2165/00002018-200427110-00004
Colombo G, Gessa GL. Tłumiący wpływ baklofenu na wiele zachowań związanych z alkoholem u zwierząt laboratoryjnych; [Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals]; Front psychiatry 9:475. doi: 10.3389/fpsyt.2018.00475
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double- blind randomized controlled study. Alcohol Alcohol (2002) 37:504–8. doi: 10.1093/alcalc/37.5.504
Agabio R, Sinclair JMA, Addolorato G, Aubin HJ, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry (2018) 5:957–60. doi: 10.1016/S2215-0366(18)30303-1
JC. Garbutt; Use of baclofen for alcohol use disorders in the United States. Front Psychiatry 9:448. doi: 10.3389/fpsyt.2018.00448
K.A. Ward; Botox A and spasticity treatment; Arch Phys Med Rehabil (1996)
E. Knutsson et al.; Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis; J Neurol Sci (1974)
P. Azouvi; Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up; Arch Phys Med Rehabil (1996)
P. Daverat, H. Petit, G. Kemoun; Długoterminowy wynik u 149 pacjentów z urazem rdzenia kręgowego. Paraplegia; [Long-term outcome in 149 patients with spinal cord injury. Paraplegia]; 1995 listopad; 33(11): 665-8
S. Knutsdottir; Urazy rdzenia kręgowego w Islandii 1973-1989: Badanie uzupełniające; [Spinal cord injuries in Iceland 1973-1989: A follow-up study.]; Paraplegia 1993 styczeń; 31(1): 68-72
L. Polacek, W. Schuppen, Wyniki czteroletniego doświadczenia z CIBA 34.647-Ba (Lioresal) w leczeniu stwardnienia rozsianego; [Results of four years experience with CIBA 34.647-Ba (Lioresal) in the treatment of multiple sclerosis.]; W: Birkmeier W, wyd. Spastyczność: aktualne badanie. Wiedeń: Huber, 1972: 123–7; Google Scholar
S. Pinto Ode, M. Polikar, G. Debono; Wyniki międzynarodowych badań klinicznych z Lioresalem; [Results of international clinical trials with Lioresal.]; Postgrad Med J 1972 Paź; 48:Dodatek. 5: 18–25; PubMed Google Scholar
RF. Jones, JW. Lance; Baklofen (Lioresal) w długotrwałym leczeniu spastyczności; [Baclofen (Lioresal) in the long-term management of spasticity.]; Środ. J Aust 1976 1 maja; 1(18): 654-7; PubMed CAS Google Scholar
RG. Feldman, M. Kelly-Hayes, JP. Conomy; Baclofen dla spastyczności w stwardnieniu rozsianym: podwójnie ślepa krzyżówka i trzyletnie studia; [Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study.]; Neurologia 1978 listopad; 28(11): 1094-8
BA. Sachais, JN. Logue, MS. Carey; Baklofen, nowy przeciwspastyczny lek: kontrolowana, wieloośrodkowa próba u pacjentów ze stwardnieniem rozsianym; [ Baclofen, a new antispastic drug: a controlled, multicenter trial in patients with multiple sclerosis.]; Arch Neurol lipiec 1977; 34(7): 422-8
LE. Krach; Farmakoterapia spastyczności: leki doustne i dokanałowy baklofen[Pharmacotherapy of spasticity: oral drugs and intrathecal baclofen]; J Dziecko Neurol 2001 styczeń; 16(1): 31-6
PV. Dicpinigaitis, DM. Nierman, A. Miller; Baclofen-induced bronchoconstriction. Ann Pharmacother 1993 Jul-Aug; 27(7-8): 883–4
N. Y Leung, I. M Whyte, G. K Isbister; Baclofen overdose: Defining the spectrum of toxicity; First published: 03 February 2006 https://doi.org/10.1111/j.1742-6723.2006.00805.x
MJ. Ellenhorn; Toksykologia medyczna Ellenhorna: diagnostyka i leczenie zatruć ludzi; [Diagnosis and Treatment of Human Poisoning.]; wyd. 2. Baltimore: Williams i Wilkins, 1997 .
D. Vandroux, B.A. Gaüzère, O. Martinet; Is extracorporeal treatment useful for managing severe baclofen poisoning even on patients with normal renal function? Indeed a very open debate!; Anaesthesia Critical Care & Pain Medicine; Volume 35, Issue 3, June 2016, Page 229
M. Vourc'h, E. Dailly, Y. Hourmant, R. Bellouard, P. J. Mahe, G. Deslandes, M. Grégoire, K. Asehnoune; Pharmacokinetics and toxicity of high-dose baclofen in ICU patients; Progress in Neuro-Psychopharmacology and Biological Psychiatry; https://doi.org/10.1016/j.pnpbp.2019.02.016
H. W. Heetla, M. J. Staal, J. H. Proost, T. van Laar; Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy; Archives of Physical Medicine and Rehabilitation; Volume 95, Issue 11, November 2014, Pages 2199-2206https://doi.org/10.1016/j.apmr.2014.04.030
Classification and Definition of Disorders Causing Hypertonia in Childhood, Pediatrics Vol. 111 No. 1 January 1, 2003 pp. e89-e97 (doi: 10.1542/peds.111.1.e89)
CSST Evaluation du rapport bénéfice/risque du Baclofène dans le traitement des patients alcoolo-dépendants, Agence Nationale de Sécurité du Médicament et des Produits de Santé, 17 kwietnia 2018 [dostęp 2018-10-06] [zarchiwizowane z adresu 2018-10-06].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gabriela Świątek, Rafał Tkaczyk, Anna Radoniewicz–Tchórz, Weronika Sosnowska, Aleksandra Brzozowska, Maria Tomkiewicz, Jakub Tomczyk, Maciej Tomkiewicz, Kornelia Trusz, Iwona Wanat
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 412
Number of citations: 0
